未登录
分享
收藏
分享
收藏TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity
Bagegni, Nusayba A.; Grigsby, Isabella; Nehring, Leslie; Luo, Jingqin; Carson, Jennifer Powers; Gibson, David W.; Horvath, Meghan; Clifton, Katherine K.; Ademuyiwa, Foluso O.; Suresh, Rama; Frith, Ashley; Davis, Andrew A.; Peterson, Lindsay L.; Bose, Ron; Williams, Amy; Bergqvist, Mattias; Ma, Cynthia
分享
收藏
分享
收藏
分享
收藏
分享
收藏